Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

← catalyst calendar

NCT05320198 · readout ≤ 284 d

Sponsored by Disc Medicine, Inc (industry) · IRON — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

150estimated

Sites

Countries

Australia, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-06-06

actual

When the study began enrolling

Primary completion

May 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jun 2027

estimated

The whole study's end, after follow-up

First posted

2022-04-11

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Myelofibrosis; Anemia
Anemia
Myelofibrosis
Myelofibrosis Due to and Following Polycythemia Vera
Primary Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Myelodysplastic Syndromes

Intervention

Drug: DISC-0974